What is Trevena?
Trevena, Inc. is a specialized biopharmaceutical enterprise dedicated to the discovery, development, and commercialization of novel medicines targeting CNS disorders. The company's market position is anchored by its FDA-approved product, OLINVYK (oliceridine) injection, which provides a targeted solution for the management of acute pain in adults. Beyond its commercialized portfolio, Trevena utilizes a proprietary research platform rooted in Nobel Prize-winning science to drive a diverse pipeline of investigational candidates. These include treatments for migraine, opioid use disorder, and diabetic neuropathic pain, positioning the firm as a key innovator in pain management and neurological health.
How much funding has Trevena raised?
Trevena has raised a total of $110.8M across 4 funding rounds:
Stock Offering
$64.8M
Other Financing Round
$40M
Share Placement
$4M
Debt
$2M
Stock Issuance/Offering (2014): $64.8M, investors not publicly disclosed
Other Financing Round (2022): $40M led by CBC Group
Share Placement (2023): $4M, investors not publicly disclosed
Debt (2024): $2M featuring R Bridge Group
Key Investors in Trevena
R Bridge Group
R Bridge Group LLC is a management consulting firm based in Germantown, Tennessee, providing strategic advisory services to support organizational growth and operational efficiency.
CBC Group
CBC Group is a prominent healthcare-focused investment firm that specializes in backing innovative life sciences companies to drive medical breakthroughs.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Trevena?
With the recent capital injection, Trevena is strategically positioned to accelerate the clinical development of its pipeline candidates, including TRV250 and TRV045. The company's forward-looking strategy focuses on optimizing the commercial reach of OLINVYK while simultaneously de-risking its investigational assets through rigorous clinical trials. Investors and stakeholders will likely monitor the firm's ability to achieve key regulatory milestones and expand its therapeutic footprint. As the biopharmaceutical industry faces increasing pressure to deliver differentiated outcomes, Trevena's focus on G protein-coupled receptor (GPCR) signaling remains a central pillar of its long-term value creation strategy.
See full Trevena company page
